vTv Therapeutics (VTVT) announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions, a United Arab Emirates-based contract research organization, has been submitted to the Department of Health Abu Dhabi. The study is designed to evaluate the safety and efficacy of cadisegliatin, an oral adjunctive therapy to insulin, in people living with type 2 diabetes. This study constitutes the longest trial investigating cadisegliatin to date and will be a 12-month, double-blind, randomized, placebo-controlled trial enrolling approximately 300 patients with type 2 diabetes who are treated with insulin for glycemic control. Participants will be randomized into three arms: two cadisegliatin dose groups and a placebo control group. The trial will take place in the UAE, Jordan, and Tunisia, with the first patient first visit expected in the first quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
- vTv Therapeutics initiated with a Buy at BTIG
- Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)
- vTv Therapeutics trading resumes